Marina Konopleva Selected Research

Doxorubicin (Adriamycin)

1/2021	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
1/2021	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
1/2019	Three-Dimensional Leukemia Co-Culture System for In Vitro High-Content Metabolomics Screening.
5/2015	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
10/2012	A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
2/2006	Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
3/2004	Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
3/2003	Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marina Konopleva Research Topics

Disease

162	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2022 - 01/2002
100	Neoplasms (Cancer) 10/2022 - 07/2002
97	Leukemia 04/2022 - 07/2002
53	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2022 - 03/2004
34	Philadelphia Chromosome 05/2022 - 10/2006
25	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 09/2006
23	Hematologic Neoplasms (Hematological Malignancy) 04/2022 - 01/2002
22	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 01/2008
15	Hypoxia (Hypoxemia) 01/2020 - 08/2009
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 10/2004
13	Lymphoma (Lymphomas) 01/2021 - 10/2004
12	Acute Promyelocytic Leukemia 01/2022 - 03/2004
10	Infections 01/2022 - 03/2004
10	Exanthema (Rash) 01/2021 - 07/2015
10	Blast Crisis (Blast Phase) 01/2021 - 10/2006
8	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 03/2014
8	Residual Neoplasm 01/2021 - 01/2017
7	Breast Neoplasms (Breast Cancer) 01/2013 - 03/2003
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 05/2007
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 03/2017
5	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
5	Disease Progression 01/2021 - 05/2017
5	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 06/2007
5	Pathologic Complete Response 07/2020 - 05/2015
4	Hypertension (High Blood Pressure) 12/2020 - 01/2011
4	Nausea 01/2020 - 07/2015
4	Mucositis 01/2019 - 06/2015
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2016 - 09/2006
4	Neoplasm Metastasis (Metastasis) 03/2014 - 05/2007
4	Hyperglycemia 10/2012 - 03/2004
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2010 - 10/2005

Drug/Important Bio-Agent (IBA)

50	venetoclaxIBA 05/2022 - 03/2014
47	Proteins (Proteins, Gene)FDA Link 10/2021 - 08/2004
26	Tyrosine Kinase InhibitorsIBA 04/2022 - 02/2010
23	Cytarabine (Cytosar-U)FDA LinkGeneric 05/2022 - 03/2004
18	TriterpenesIBA 06/2012 - 01/2002
15	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 06/2013
15	Phosphotransferases (Kinase)IBA 02/2017 - 04/2006
15	bardoxoloneIBA 12/2010 - 01/2002
14	Pharmaceutical PreparationsIBA 01/2022 - 08/2004
12	bardoxolone methylIBA 08/2014 - 01/2002
11	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 02/2008
10	AcidsIBA 11/2007 - 09/2003
9	ponatinibIBA 05/2022 - 09/2014
8	tagraxofuspIBA 10/2022 - 07/2014
8	fms-Like Tyrosine Kinase 3IBA 01/2022 - 04/2006
8	fludarabineIBA 12/2021 - 08/2006
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 03/2004
8	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 08/2021 - 11/2013
8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 03/2003
8	Decitabine FDA Link 01/2021 - 09/2012
8	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 05/2002
7	Dasatinib (BMS 354825)FDA Link 05/2022 - 01/2017
7	Oxygen (Dioxygen)IBA 10/2021 - 01/2010
7	ABT-737IBA 09/2021 - 11/2006
7	Biomarkers (Surrogate Marker)IBA 06/2021 - 07/2012
7	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 03/2004
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 01/2010
7	Imatinib Mesylate (Gleevec)FDA Link 01/2016 - 10/2006
6	blinatumomabIBA 01/2022 - 12/2017
6	Inotuzumab OzogamicinIBA 01/2022 - 01/2018
6	Clofarabine (Clolar)FDA Link 01/2021 - 09/2012
6	LigandsIBA 11/2020 - 07/2002
6	ProdrugsIBA 05/2017 - 01/2011
6	TOR Serine-Threonine KinasesIBA 11/2015 - 09/2006
6	EstersIBA 12/2010 - 01/2002
6	PPAR gammaIBA 06/2010 - 07/2002
5	Transaminases (Aminotransferases)IBA 10/2022 - 11/2017
5	Glutamine (L-Glutamine)FDA Link 01/2022 - 11/2013
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 02/2006
5	ibrutinibIBA 12/2021 - 05/2015
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 03/2004
5	Protein Isoforms (Isoforms)IBA 01/2021 - 03/2003
5	nutlin 3IBA 01/2017 - 08/2006
5	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 03/2004
5	bcr-abl Fusion ProteinsIBA 01/2016 - 10/2006
4	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2022 - 12/2011
4	Asparaginase (Elspar)FDA Link 01/2022 - 11/2013
4	IACS-010759IBA 01/2022 - 01/2018
4	GlutaminaseIBA 01/2022 - 11/2016
4	CreatinineIBA 01/2022 - 10/2011
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022 - 04/2005
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2020 - 06/2009
4	plerixafor FDA Link 11/2020 - 01/2013
4	Adenosine Triphosphate (ATP)IBA 01/2019 - 01/2010
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 12/2007
4	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 05/2015
4	CXCR4 Receptors (CXCR4 Receptor)IBA 03/2017 - 03/2007
4	Messenger RNA (mRNA)IBA 01/2017 - 06/2010
4	Tyrosine (L-Tyrosine)FDA Link 02/2016 - 01/2008
4	Everolimus FDA Link 06/2015 - 09/2006
4	Sirolimus (Rapamycin)FDA Link 02/2015 - 04/2007
4	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 12/2008 - 07/2005
4	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acidIBA 12/2008 - 04/2004

Therapy/Procedure

106	Therapeutics 04/2022 - 09/2003
64	Drug Therapy (Chemotherapy) 05/2022 - 11/2004
13	Stem Cell Transplantation 10/2021 - 07/2007
6	Induction Chemotherapy 09/2019 - 03/2004
5	Hematopoietic Stem Cell Transplantation 01/2021 - 05/2007
4	Salvage Therapy 01/2021 - 09/2015